menu
    • menu

    Company profile for GSK

    Evonik

    Virtual Booth

    Contact Supplier

    Sharp is a global leader in pharmaceutical packaging and clinical trial supply services.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At GSK we have a challenging mission: to improve the quality of human life by enabling people to do more, feel better, live longer. Find out how this shapes everything we do, including our R&D, our partnerships, our work with communities and our efforts to prevent and treat disease around the world. We are a science-led global healthcare company with a mission: we want to help people to do more, feel better, live longer. The...
    At GSK we have a challenging mission: to improve the quality of human life by enabling people to do more, feel better, live longer. Find out how this shapes everything we do, including our R&D, our partnerships, our work with communities and our efforts to prevent and treat disease around the world. We are a science-led global healthcare company with a mission: we want to help people to do more, feel better, live longer. The vaccines, medicines and consumer healthcare products that we research and develop can improve people’s health and well-being, ultimately helping them to live life to its fullest and contribute.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GSKunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    980 Great West Road, Brentford, Middlesex TW8 9GS England
    Telephone
    Telephone
    +44 (0)20 8047 5000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gsk.com:443/en-gb/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 949

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2068

    https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

    #PharmaFlow by PHARMACOMPASS
    24 Apr 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    UK approves therapies of GSK's blood cancer drug Blenrep
    UK approves therapies of GSK's blood cancer drug Blenrep

    19 Apr 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/uk-approves-combination-therapies-gsks-blood-cancer-drug-blenrep-2025-04-17/

    REUTERS
    19 Apr 2025
    Share Share
    GSK in breach for misleading prescription information on Omjjara
    GSK in breach for misleading prescription information on Omjjara

    16 Apr 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-breach-misleading-prescribing-information-omjjara-industry-body-says-2025-04-15/

    REUTERS
    16 Apr 2025
    Share Share
    GSK scolded over 'shocking error' in prescribing information
    GSK scolded over 'shocking error' in prescribing information

    16 Apr 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/gsk-scolded-after-complainant-flags-shocking-error-prescribing-information

    FIERCE PHARMA
    16 Apr 2025
    Share Share
    Arexy Recommended for adults 50-59 at increased RSV risk
    Arexy Recommended for adults 50-59 at increased RSV risk

    16 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250415426978/en/AREXVY-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-RSV-disease-by-US-Advisory-Committee-on-Immunization-Practices

    BUSINESSWIRE
    16 Apr 2025
    Share Share
    GSK awards $2M grant for adult vaccination, pledges $2M more by 2o25
    GSK awards $2M grant for adult vaccination, pledges $2M more by 2o25

    09 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250408389277/en/GSK-Awards-%242M-in-Grant-Funding-for-Programs-Supporting-Adult-Vaccination-Commits-Additional-%242M-for-2025

    BUSINESSWIRE
    09 Apr 2025
    Share Share
    ABL Bio, GSK partner on Brain Delivery Platform for Diseases
    ABL Bio, GSK partner on Brain Delivery Platform for Diseases

    08 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abl-bio-announces-grabody-b-brain-delivery-platform-license-agreement-with-gsk-to-develop-novel-medicines-for-neurodegenerative-diseases-302421547.html

    PR NEWSWIRE
    08 Apr 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    GSK's Blenrep Combinations Approved by UK MHRA in Relapsed/refractory Multiple Myeloma

    Details:

    Blenrep (belantamab mafodotin-blmf) is an anti-BCMA ADC. It is being evaluated in combination with pomalidomide, bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.


    Lead Product(s): Belantamab Mafodotin,Bortezomib,Dexamethasone

    Therapeutic Area: Oncology Brand Name: Blenrep

    Study Phase: Approved FDFProduct Type: Antibody-drug Conjugate

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 19, 2025

    blank

    01

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Belantamab Mafodotin,Bortezomib,Dexamethasone

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    GSK's Blenrep Combinations Approved by UK MHRA in Relapsed/refractory Multiple Myeloma

    Details : Blenrep (belantamab mafodotin-blmf) is an anti-BCMA ADC. It is being evaluated in combination with pomalidomide, bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

    Product Name : Blenrep

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    April 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ABL Bio Licenses Brain Drug Platform to GSK for Neuro Diseases

    Details:

    Under the licensing agreement, GSK will develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B.


    Lead Product(s): Undisclosed

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Oligonucleotide

    Recipient: ABL Bio

    Deal Size: $101.9 million Upfront Cash: $49.6 million

    Deal Type: Licensing Agreement April 06, 2025

    blank

    02

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Neurology

    Highest Development Status : Discovery Platform

    Recipient : ABL Bio

    Deal Size : $101.9 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    ABL Bio Licenses Brain Drug Platform to GSK for Neuro Diseases

    Details : Under the licensing agreement, GSK will develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B.

    Product Name : Undisclosed

    Product Type : Oligonucleotide

    Upfront Cash : $49.6 million

    April 06, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Blujepa (Gepotidacin) FDA-Approved for Uncomplicated Urinary Tract Infections

    Details:

    Blujepa (gepotidacin) is the first in a new class of oral antibiotics which inhibits topoisomerase II/IV. It is approved for the treatment of uncomplicated urinary tract infections.


    Lead Product(s): Gepotidacin

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Blujepa

    Study Phase: Approved FDFProduct Type: Antibiotic

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 25, 2025

    blank

    03

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gepotidacin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Blujepa (Gepotidacin) FDA-Approved for Uncomplicated Urinary Tract Infections

    Details : Blujepa (gepotidacin) is the first in a new class of oral antibiotics which inhibits topoisomerase II/IV. It is approved for the treatment of uncomplicated urinary tract infections.

    Product Name : Blujepa

    Product Type : Antibiotic

    Upfront Cash : Inapplicable

    March 25, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    EMA Reviews GSK’s Nucala Expansion for COPD Treatment

    Details:

    Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is being investigated for the treament of COPD with an eosinophilic phenotype.


    Lead Product(s): Mepolizumab

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Nucala

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 24, 2025

    blank

    04

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mepolizumab

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    EMA Reviews GSK’s Nucala Expansion for COPD Treatment

    Details : Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is being investigated for the treament of COPD with an eosinophilic phenotype.

    Product Name : Nucala

    Product Type : Antibody

    Upfront Cash : Inapplicable

    March 24, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ViiV’s N6LS Antibody Maintains Long-Acting Viral Suppression in HIV Treatment

    Details:

    VH109, a CD4-binding broadly neutralising antibody, in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV.


    Lead Product(s): VH109,Cabotegravir

    Therapeutic Area: Infections and Infectious Diseases Brand Name: VH3810109

    Study Phase: Phase IIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 12, 2025

    blank

    05

    ViiV Healthcare

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    ViiV Healthcare

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VH109,Cabotegravir

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    ViiV’s N6LS Antibody Maintains Long-Acting Viral Suppression in HIV Treatment

    Details : VH109, a CD4-binding broadly neutralising antibody, in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV.

    Product Name : VH3810109

    Product Type : Antibody

    Upfront Cash : Inapplicable

    March 12, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    US FDA Approves GSK's Combo Meningococcal Vaccine

    Details:

    Penmenvy approved for use in individuals aged 10 to 25 years. The vaccine targets 5 major serogroups of Neisseria meningitidis (A, B, C, W, & Y) which commonly cause invasive meningococcal disease.


    Lead Product(s): Meningococcal Groups A, B, C, W, and Y Vaccine

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Penmenvy

    Study Phase: Approved FDFProduct Type: Vaccine

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 15, 2025

    blank

    06

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Meningococcal Groups A, B, C, W, and Y Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    US FDA Approves GSK's Combo Meningococcal Vaccine

    Details : Penmenvy approved for use in individuals aged 10 to 25 years. The vaccine targets 5 major serogroups of Neisseria meningitidis (A, B, C, W, & Y) which commonly cause invasive meningococcal disease.

    Product Name : Penmenvy

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    February 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    EMA Reviews Depemokimab for Asthma with Type 2 Inflammation and CRSwNP

    Details:

    GSK3511294 (depemokimab) is the first ultra-long-acting biologic with a binding affinity for IL-5. It is being evaluated for the treatment of severe asthma With an eosinophilic phenotype.


    Lead Product(s): Depemokimab

    Therapeutic Area: Infections and Infectious Diseases Brand Name: GSK3511294

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 28, 2025

    blank

    07

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Depemokimab

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    EMA Reviews Depemokimab for Asthma with Type 2 Inflammation and CRSwNP

    Details : GSK3511294 (depemokimab) is the first ultra-long-acting biologic with a binding affinity for IL-5. It is being evaluated for the treatment of severe asthma With an eosinophilic phenotype.

    Product Name : GSK3511294

    Product Type : Antibody

    Upfront Cash : Inapplicable

    January 28, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    EMA Reviews GSK’s Shingrix New Prefilled Syringe Presentation

    Details:

    Shingrix (recombinant zoster vaccine) is a non-live, recombinant subunit vaccine, being evaluated as a prefilled syringe administration for prevention of shingles in at-risk adults aged 18 and over.


    Lead Product(s): Zoster Vaccine Recombinant, Adjuvanted

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Shingrix

    Study Phase: Phase IIIProduct Type: Vaccine

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 27, 2025

    blank

    08

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Zoster Vaccine Recombinant, Adjuvanted

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    EMA Reviews GSK’s Shingrix New Prefilled Syringe Presentation

    Details : Shingrix (recombinant zoster vaccine) is a non-live, recombinant subunit vaccine, being evaluated as a prefilled syringe administration for prevention of shingles in at-risk adults aged 18 and over.

    Product Name : Shingrix

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    January 27, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    GSK’s Nucala Bags Another China Approval, but Biggest Test Yet to Come

    Details:

    Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is approved as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps.


    Lead Product(s): Mepolizumab

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Nucala

    Study Phase: Approved FDFProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 03, 2025

    blank

    09

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mepolizumab

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    GSK’s Nucala Bags Another China Approval, but Biggest Test Yet to Come

    Details : Nucala (mepolizumab) is the first targeted anti-Interleukin-5 (IL-5) biologic. It is approved as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps.

    Product Name : Nucala

    Product Type : Antibody

    Upfront Cash : Inapplicable

    January 03, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    GSK Announces FIRST Trial Met Primary Endpoint in Advanced Ovarian Cancer

    Details:

    Jemperli (dostarlimab, targets PD-1) in combination with Zejula (niraparib, targets PARP) is being evaluated as a first line treatment in phase 3 ciical trials of ovarian cancer.


    Lead Product(s): Dostarlimab,Niraparib Tosylate

    Therapeutic Area: Oncology Brand Name: Jemperli

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 20, 2024

    blank

    10

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed

    GSK

    United Kingdom
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dostarlimab,Niraparib Tosylate

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    GSK Announces FIRST Trial Met Primary Endpoint in Advanced Ovarian Cancer

    Details : Jemperli (dostarlimab, targets PD-1) in combination with Zejula (niraparib, targets PARP) is being evaluated as a first line treatment in phase 3 ciical trials of ovarian cancer.

    Product Name : Jemperli

    Product Type : Antibody

    Upfront Cash : Inapplicable

    December 20, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Sierra Oncology and get a quotation

    Sierra Oncology is a supplier offers 142 products (APIs, Excipients or Intermediates).

    Find a price of Cefuroxime Sodium bulk with DMF, CEP offered by Sierra Oncology

    Find a price of Fluticasone Propionate bulk with DMF, CEP offered by Sierra Oncology

    Find a price of Amoxicillin Trihydrate bulk with CEP offered by Sierra Oncology

    Find a price of Betamethasone Valerate bulk with CEP offered by Sierra Oncology

    Find a price of Ceftazidime bulk with CEP offered by Sierra Oncology

    Find a price of Clavulanic Acid bulk with CEP offered by Sierra Oncology

    Find a price of Clobetasol Propionate bulk with CEP offered by Sierra Oncology

    Find a price of Salbutamol Sulphate bulk with CEP offered by Sierra Oncology

    Find a price of Ceftazidime bulk with DMF offered by Sierra Oncology

    Find a price of Cefuroxime Axetil bulk offered by Sierra Oncology

    Find a price of Clavulanic Acid bulk offered by Sierra Oncology

    Find a price of Fluticasone Furoate bulk with DMF offered by Sierra Oncology

    Find a price of Fluticasone Propionate bulk with DMF offered by Sierra Oncology

    Find a price of Griseofulvin bulk offered by Sierra Oncology

    Find a price of Labetalol Hydrochloride bulk offered by Sierra Oncology

    Find a price of Mupirocin Calcium bulk offered by Sierra Oncology

    Find a price of Paroxetine Hydrochloride bulk with DMF offered by Sierra Oncology

    Find a price of Salbutamol Sulphate bulk with DMF offered by Sierra Oncology

    Find a price of Salmeterol Xinafoate bulk with DMF offered by Sierra Oncology

    Find a price of Umeclidinium Bromide bulk with DMF offered by Sierra Oncology

    Find a price of Vilanterol Trifenatate bulk with DMF offered by Sierra Oncology

    Find a price of bulk with JDMF offered by Sierra Oncology

    Find a price of 6-Aminopenicillanic Acid bulk offered by Sierra Oncology

    Find a price of Albendazole bulk offered by Sierra Oncology

    Find a price of Amoxicillin Sodium bulk offered by Sierra Oncology

    Find a price of Amoxicillin Trihydrate bulk offered by Sierra Oncology

    Find a price of Ampicillin bulk offered by Sierra Oncology

    Find a price of Ampicillin Sodium bulk offered by Sierra Oncology

    Find a price of Ampicillin Trihydrate bulk offered by Sierra Oncology

    Find a price of Auranofin bulk offered by Sierra Oncology

    Find a price of Beclomethasone Dipropionate bulk offered by Sierra Oncology

    Find a price of Betamethasone Dipropionate bulk offered by Sierra Oncology

    Find a price of Betamethasone Valerate bulk offered by Sierra Oncology

    Find a price of Calcitonin bulk offered by Sierra Oncology

    Find a price of Caramiphen Ethanedisulfonate bulk offered by Sierra Oncology

    Find a price of Carbenicillin Indanyl bulk offered by Sierra Oncology

    Find a price of Cephalexin bulk offered by Sierra Oncology

    Find a price of Cephalosporin bulk offered by Sierra Oncology

    Find a price of Cephradine bulk offered by Sierra Oncology

    Find a price of Chlorpheniramine Maleate bulk offered by Sierra Oncology

    Find a price of Cimetidine bulk offered by Sierra Oncology

    Find a price of Clobetasol Propionate bulk offered by Sierra Oncology

    Find a price of Clobetasone Butyrate bulk offered by Sierra Oncology

    Find a price of Cloxacillin Benzathine bulk offered by Sierra Oncology

    Find a price of Cloxacillin Sodium bulk offered by Sierra Oncology

    Find a price of Deoxyuridine bulk offered by Sierra Oncology

    Find a price of Diethylcarbamazine Citrate bulk offered by Sierra Oncology

    Find a price of Diphenidol bulk offered by Sierra Oncology

    Find a price of Diphenylpyraline bulk offered by Sierra Oncology

    Find a price of Dopamine bulk offered by Sierra Oncology

    Find a price of Doxepin Hydrochloride bulk offered by Sierra Oncology

    Find a price of Fondaparinux Sodium bulk offered by Sierra Oncology

    Find a price of Hydrochlorothiazide bulk offered by Sierra Oncology

    Find a price of Isopropamide Iodide bulk offered by Sierra Oncology

    Find a price of Liothyronine Sodium bulk offered by Sierra Oncology

    Find a price of Megestrol Acetate bulk offered by Sierra Oncology

    Find a price of Methicillin bulk offered by Sierra Oncology

    Find a price of Mupirocin bulk offered by Sierra Oncology

    Find a price of Nafcillin Sodium bulk offered by Sierra Oncology

    Find a price of Oxacillin Sodium bulk offered by Sierra Oncology

    Find a price of Paroxetine Hydrochloride bulk offered by Sierra Oncology

    Find a price of Penicillin G Potassium bulk offered by Sierra Oncology

    Find a price of Propyliodone bulk offered by Sierra Oncology

    Find a price of Sodium Dicloxacillin bulk offered by Sierra Oncology

    Find a price of Streptokinase bulk offered by Sierra Oncology

    Find a price of Streptomycin bulk offered by Sierra Oncology

    Find a price of Sucralfate bulk offered by Sierra Oncology

    Find a price of Tetanus Immunoglobulin bulk offered by Sierra Oncology

    Find a price of Ticarcillin bulk offered by Sierra Oncology

    Find a price of Ticarcillin Monosodium bulk offered by Sierra Oncology

    Find a price of Tranylcypromine Sulfate bulk offered by Sierra Oncology

    Find a price of Trifluoperazine Hydrochloride bulk offered by Sierra Oncology

    Find a price of Vitamin B12 bulk offered by Sierra Oncology

    Find a price of Zidovudine bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND GENERAL OPERATING PROCEDURES IN SINGAPORE bulk offered by Sierra Oncology

    Find a price of COMPOUND 904 bulk offered by Sierra Oncology

    Find a price of BUILDINGS AND FACILITIES IN SEALS SANDS, ENGLAND bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MONTROSE, ANGEES, SCOTLAND. bulk offered by Sierra Oncology

    Find a price of MFG. SITE FACILITIES UTILIZED IN SPEKE LIVERPOOL (UK) bulk offered by Sierra Oncology

    Find a price of FACILITIES&CONTROLS AT HARLOW AND GREAT BURGH RESEARCH SITES, ENGLAND bulk offered by Sierra Oncology

    Find a price of ENTRENOL bulk offered by Sierra Oncology

    Find a price of FACIL, PERSONNEL AND GENERAL OPERATING PROCEDURES IN HARLOW, ESSEX. bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN CAROLINA, PUERTO RICO. bulk offered by Sierra Oncology

    Find a price of FACILITIES & CONTROLS OF THE WELLCOME FOUNDATION IN KENT ENGLAND bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN CIDRA, PUERTO RICO. bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES. bulk offered by Sierra Oncology

    Find a price of MFGR, CONTROL PROCEDURES & FACILITIES-MYERSTOWN, PA., PLANT bulk offered by Sierra Oncology

    Find a price of MANUFACTURING FACILITY AT VERONA, ITALY. bulk offered by Sierra Oncology

    Find a price of MANUFACTURING PRODUCTION FACILITY IN TORONTO, CANADA bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PESONNEL, AND GENERAL OPERATING PROCEDURES IN WEST SUSSEX, ENGLAND. bulk offered by Sierra Oncology

    Find a price of FACILITIES AND OPERATING PROCEDURES IN TIANJIN, CHINA bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE AND FACILITIES FOR ANNAN, UK PLANT bulk offered by Sierra Oncology

    Find a price of MFG. FACILITIES LOCATED IN JURONG, SINGAPORE bulk offered by Sierra Oncology

    Find a price of 7-ACA TOSYLATE bulk offered by Sierra Oncology

    Find a price of FACILITIES AND MANUFACTURING bulk offered by Sierra Oncology

    Find a price of PENN CHEMICALS PRODUCTION FACILITY IN COUNTY CORK, IRELAND bulk offered by Sierra Oncology

    Find a price of GENERAL OPERATING PROCEDURES SINGAPORE PLANT bulk offered by Sierra Oncology

    Find a price of FACIL, PERSONNEL & GENL OPER PROCED IN GREAT BURGH, EPSOM, U.K. bulk offered by Sierra Oncology

    Find a price of CLENOLIXIMAB [CHIMERIC (MACAQUE/HUMAN) MONOCLONAL ANTIBODY (SB-217969) (CHO CELLS, SMITHKLINE BEECHAM) TO CD4] bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN TONBRIDGE, KENT, ENGLAND. bulk offered by Sierra Oncology

    Find a price of L-DM1 bulk offered by Sierra Oncology

    Find a price of ASO1B ADJUVANT SYSTEM bulk offered by Sierra Oncology

    Find a price of FACILITIES, METHODS AND CONTROLS bulk offered by Sierra Oncology

    Find a price of BRL 47539 (2-ACETOXYMETHYL-4-IODOBUT-1-YL-ACETATE) bulk offered by Sierra Oncology

    Find a price of O/4 DIHYDROCHLORIDE DIHYRATE (CPZ ROUTE) bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BOMBAY, INDIA. bulk offered by Sierra Oncology

    Find a price of FACILITY IN BUCKHAVEN, UNITED KINGDOM bulk offered by Sierra Oncology

    Find a price of 0/4 DIHYDROCHLORIDE DIHYDRATE (CEPHALORIDINE ROUTE-CP)-ULVERSTON PLANT bulk offered by Sierra Oncology

    Find a price of FACILITIES UTILIZED IN WARE HERTS, UNITED KINGDOM bulk offered by Sierra Oncology

    Find a price of FACILS AND GEN OPER PROCEDS AT THE ULVERSTON PLANT bulk offered by Sierra Oncology

    Find a price of SYNTHESIS & QUALITY CONTROLS FOR 5,7-DICHLORO-8-HYDROXYQUINOLONE bulk offered by Sierra Oncology

    Find a price of FACILITY LOCATED IN EDINBURG, SCOTLAND bulk offered by Sierra Oncology

    Find a price of GENERAL OPERATING PROCEDURES FOR THE HEPPIGIES, BELGIUM--ANTIBIOTICS bulk offered by Sierra Oncology

    Find a price of 'ZENTEL' 'TILTAB' TABLETS bulk offered by Sierra Oncology

    Find a price of CHIMERIC (MACAQUE VARIABLE/HUMAN CONSTANT) (RECOMBINANT, CHO CELLS) MONOCLONAL ANTIBODY (SB 210396; CE9.1) TO HUMAN CD4 ANTIGEN bulk offered by Sierra Oncology

    Find a price of HIV VACCINE (GPL 120/NEFTA/ASO2A) bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GREENVILLE, NORTH CAROLINA. bulk offered by Sierra Oncology

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN CUERNAVACA, MEXICO. bulk offered by Sierra Oncology

    Find a price of Abacavir Sulfate bulk offered by Sierra Oncology

    Find a price of Benzyl Penicillin bulk offered by Sierra Oncology

    Find a price of Cabotegravir bulk offered by Sierra Oncology

    Find a price of Cabotegravir Sodium bulk offered by Sierra Oncology

    Find a price of CAS 103639-04-9 bulk offered by Sierra Oncology

    Find a price of Daprodustat bulk offered by Sierra Oncology

    Find a price of Dolutegravir Sodium bulk offered by Sierra Oncology

    Find a price of Dutasteride bulk offered by Sierra Oncology

    Find a price of Epsiprantel bulk offered by Sierra Oncology

    Find a price of Fluticasone Furoate bulk offered by Sierra Oncology

    Find a price of Lacidipine bulk offered by Sierra Oncology

    Find a price of Lamivudine bulk offered by Sierra Oncology

    Find a price of Nabumetone bulk offered by Sierra Oncology

    Find a price of Naratriptan Hydrochloride bulk offered by Sierra Oncology

    Find a price of Nelarabine bulk offered by Sierra Oncology

    Find a price of Ondansetron bulk offered by Sierra Oncology

    Find a price of Pazopanib Hydrochloride bulk offered by Sierra Oncology

    Find a price of Ranitidine Hydrochloride bulk offered by Sierra Oncology

    Find a price of Retapamulin bulk offered by Sierra Oncology

    Find a price of Trametinib bulk offered by Sierra Oncology

    Find a price of Umeclidinium Bromide bulk offered by Sierra Oncology

    Find a price of Vilanterol Trifenatate bulk offered by Sierra Oncology

    Find a price of Zanamivir bulk offered by Sierra Oncology

    Find a price of MEDICATED FEED bulk offered by Sierra Oncology

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search